Systemic inflammation score predicts postoperative prognosis of patients with clear-cell renal cell carcinoma

British Journal of Cancer

Volumn 113, Issue 4, 2015, Pages 626-633

  Chang, Y ^a   An, H ^a   Xu, L ^a   Zhu, Y ^b   Yang, Y ^a   Lin, Z ^a   Xu, J ^a  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

Author keywords

biomarker; inflammation; nomogram; prognosis; renal cell carcinoma

Indexed keywords

HEMOGLOBIN; SERUM ALBUMIN;

ADULT; ARTICLE; BLOOD CELL RATIO; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; DIAGNOSTIC VALUE; FEMALE; HUMAN; KIDNEY CARCINOMA; LYMPH VESSEL METASTASIS; LYMPHOCYTE MONOCYTE RATIO; MAJOR CLINICAL STUDY; MALE; NOMOGRAM; OVERALL SURVIVAL; PATHOLOGY; POSTOPERATIVE CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SYSTEMIC INFLAMMATION SCORE; TUMOR NECROSIS; TUMOR VOLUME; UROGENITAL TRACT DISEASE ASSESSMENT; CARCINOMA, RENAL CELL; DISEASE COURSE; INFLAMMATION; KIDNEY NEOPLASMS; LYMPHOCYTE; MIDDLE AGED; MONOCYTE; NECROSIS; NEPHRECTOMY; POSTOPERATIVE PERIOD; PROCEDURES; PROGNOSIS;

CARCINOMA, RENAL CELL; DISEASE PROGRESSION; FEMALE; HUMANS; INFLAMMATION; KIDNEY NEOPLASMS; LYMPHOCYTES; MALE; MIDDLE AGED; MONOCYTES; NECROSIS; NEPHRECTOMY; POSTOPERATIVE PERIOD; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 84939168836     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.241     Document Type: Article

References (25)

1. Balkwill F, Mantovani A. (2001). Inflammation and cancer: back to Virchow?. Lancet. 357(9255): 539-545.
2. Chechlinska M, Kowalewska M, Nowak R. (2010). Systemic inflammation as a confounding factor in cancer biomarker discovery and validation. Nat Rev Cancer. 10(1): 2-3.
3. Dunn GP, Old LJ, Schreiber RD. (2004). The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 21(2): 137-148.
4. Edge SB, Compton CC. (2010). The American Joint Committee on Cancer: the. 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 17(6): 1471-1474.
5. Esper DH, Harb WA. (2005). The cancer cachexia syndrome: a review of metabolic and clinical manifestations. Nutr Clin Pract. 20(4): 369-376.
6. Fox P, Hudson M, Brown C, Lord S, Gebski V, De Souza P, Lee CK. (2013). Markers of systemic inflammation predict survival in patients with advanced renal cell cancer. Br J Cancer. 109(1): 147-153.
7. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. (2002). An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol. 168(6): 2395-2400.
8. Fuhrman SA, Lasky LC, Limas C. (1982). Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 6(7): 655-663.
9. Gupta D, Lis CG. (2010). Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J. 9: 69.
10. Harrell Jr. FE, Lee KL, Mark DB. (1996). Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 15(4): 361-387.
11. Hermanns T, Bhindi B, Wei Y, Yu J, Noon AP, Richard PO, Bhatt JR, Almatar A, Jewett MA, Fleshner NE, Zlotta AR, Templeton AJ, Kulkarni GS. (2014). Pre-Treatment neutrophil-To-lymphocyte ratio as predictor of adverse outcomes in patients undergoing radical cystectomy for urothelial carcinoma of the bladder. Br J Cancer. 111(3): 444-451.
12. Hutterer GC, Stoeckigt C, Stojakovic T, Jesche J, Eberhard K, Pummer K, Zigeuner R, Pichler M. (2014). Low preoperative lymphocyte-monocyte ratio (LMR) represents a potentially poor prognostic factor in nonmetastatic clear cell renal cell carcinoma. Urol Oncol. 32(7): 1041-1048.
13. Karakiewicz PI, Trinh QD, Lam JS, Tostain J, Pantuck AJ, Belldegrun AS, Patard JJ. (2007). Platelet count and preoperative haemoglobin do not significantly increase the performance of established predictors of renal cell carcinoma-specific mortality. Eur Urol. 52(5): 1428-1436.
14. Krenn-Pilko S, Langsenlehner U, Thurner EM, Stojakovic T, Pichler M, Gerger A, Kapp KS, Langsenlehner T. (2014). The elevated preoperative platelet-To-lymphocyte ratio predicts poor prognosis in breast cancer patients. Br J Cancer. 110(10): 2524-2530.
15. Ljungberg B, Campbell SC, Choi HY, Jacqmin D, Lee JE, Weikert S, Kiemeney LA. (2011). The epidemiology of renal cell carcinoma. Eur Urol. 60(4): 615-621.
16. Mantovani A. (2009). Cancer: inflaming metastasis. Nature. 457(7225): 36-37.
17. Mantovani A, Allavena P, Sica A, Balkwill F. (2008). Cancer-related inflammation. Nature. 454(7203): 436-444.
18. McMillan DC. (2008). An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer. Proc Nutr Soc. 67(3): 257-262.
19. McMillan DC. (2009). Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care. 12(3): 223-226.
20. McMillan DC. (2013). The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev. 39(5): 534-540.
21. Morgan TM, Tang D, Stratton KL, Barocas DA, Anderson CB, Gregg JR, Chang SS, Cookson MS, Herrell SD, Smith Jr. JA, Clark PE. (2011). Preoperative nutritional status is an important predictor of survival in patients undergoing surgery for renal cell carcinoma. Eur Urol. 59(6): 923-928.
22. Pichler M, Hutterer GC, Stoeckigt C, Chromecki TF, Stojakovic T, Golbeck S, Eberhard K, Gerger A, Mannweiler S, Pummer K, Zigeuner R. (2013). Validation of the pre-Treatment neutrophil-lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients. Br J Cancer. 108(4): 901-907.
23. Qian BZ, Pollard JW. (2010). Macrophage diversity enhances tumor progression and metastasis. Cell. 141(1): 39-51.
24. Shariat SF, Xylinas E. (2012). Biomarkers in personalised treatment of renalcell carcinoma. Lancet Oncol. 13(8): 751-752.
25. Szkandera J, Gerger A, Liegl-Atzwanger B, Absenger G, Stotz M, Friesenbichler J, Trajanoski S, Stojakovic T, Eberhard K, Leithner A, Pichler M. (2014). The lymphocyte/monocyte ratio predicts poor clinical outcome and improves the predictive accuracy in patients with soft tissue sarcomas. Int J Cancer. 135(2): 362-370.